The ASX is notorious for undervaluation of new tech which explains why so many leave these shores. Page 15 of the link I provided clearly shows the valuation of medtech. The world hasn't changed, growth opportunities remain scarce, and medical advancements are top of the valuation tree in the minds of investors, i.e. x15 to x40 revenues, these are facts, backed by data. Stockrock has made some decent points, I don't agree with his framework and so some of his conclusions are strange to me, but I still don't believe he is being malicious. Lighten up.
Ann: 1H FY22 Results - Webcast Recording, page-96
-
- There are more pages in this discussion • 152 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.54 |
Change
-0.180(6.62%) |
Mkt cap ! $1.753B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.65 | $2.53 | $4.356M | 1.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 29641 | $2.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.55 | 22158 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |